The NCCN 2014 Nursing Program Webinar Series: Advancing Oncology Nursing Live Webinar Series will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

Brentuximab vedotin is an antibody-drug conjugate FDA-approved for the treatment of systemic anaplastic large-cell lymphoma (ALCL) that has relapsed after multiagent chemotherapy.

The NPM-ALK fusion protein is found in ALK+ anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%.

Join John Byrd, MD, and Gerard Lozanski, MD, as they present their multidisciplinary expertise on a range of cases pertaining to CLL/SLL.

The NCCN 2014 Oncology Nursing Program at the NCCN 19th Annual Conference will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

Join John Byrd, MD, and Gerard Lozanski, MD, as they present their multidisciplinary expertise on a range of cases pertaining to CLL/SLL.

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphoma (NHL) and provide a discussion of the clinical evidence that support the updates.

This information was originally presented on September 14, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 14, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 14, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.